当归补血汤合六味地黄汤对高血压肝肾阴虚证早期肾损害的防治

陈小永; 王自闯; 郭存霞; 王琳娜

doi:10.13422/j.cnki.syfjx.2017090190

您当前的位置：

首页 >

文章列表页 >

当归补血汤合六味地黄汤对高血压肝肾阴虚证早期肾损害的防治

临床 | 更新时间：2024-01-04

- 当归补血汤合六味地黄汤对高血压肝肾阴虚证早期肾损害的防治
- Preventive and Treatment Effect of Danggui Buxuetang and Liuwei Dihuang Tang on Early Hypertensive Renal Damage
- 中国实验方剂学杂志 2017年23卷第9期页码：190-195
- 作者机构：
- 作者简介：
- 基金信息：
  
  河南省中医药科学研究专项（2014ZY02021）
- DOI：10.13422/j.cnki.syfjx.2017090190
  中图分类号： R259
- 纸质出版日期：2017
- 稿件说明：
移动端阅览
陈小永, 王自闯, 郭存霞, 等. 当归补血汤合六味地黄汤对高血压肝肾阴虚证早期肾损害的防治[J]. 中国实验方剂学杂志, 2017,23(9):190-195.

CHEN Xiao-yong, WANG Zi-chuang, GUO Cun-xia, et al. Preventive and Treatment Effect of Danggui Buxuetang and Liuwei Dihuang Tang on Early Hypertensive Renal Damage[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(9): 190-195.
陈小永, 王自闯, 郭存霞, 等. 当归补血汤合六味地黄汤对高血压肝肾阴虚证早期肾损害的防治[J]. 中国实验方剂学杂志, 2017,23(9):190-195. DOI： 10.13422/j.cnki.syfjx.2017090190.

CHEN Xiao-yong, WANG Zi-chuang, GUO Cun-xia, et al. Preventive and Treatment Effect of Danggui Buxuetang and Liuwei Dihuang Tang on Early Hypertensive Renal Damage[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(9): 190-195. DOI： 10.13422/j.cnki.syfjx.2017090190.

摘要

目的：观察当归补血汤合六味地黄汤治疗早期高血压肾损害的临床疗效及对转化生长因子-β1（TGF-β1），纤溶酶原激活物抑制剂-1（PAI-1），白细胞介素-1β（IL-1β）和肿瘤坏死因子-α（TNF-α）水平的影响。方法： 240例患者采用区组分层随机，以SAS软件生成的数字表法，按1：1分为观察组和对照组各120例。基础治疗口服缬沙坦胶囊，80 mg/次，1次/d；血压未达标加用硝苯地平控释片，1片/次，1次/d。对照组采用六味地黄汤，1剂/d，分早晚2次内服；观察组采用当归补血汤合六味地黄汤，1剂/d，分早晚2次内服。两组疗程均为12周。检测尿血清β2微球蛋白（β2-MG），尿N-乙酰-β-氨基葡萄糖苷酶（NAG），胱抑素C（CysC）水平，微量白蛋白（mALB），血肌酐（SCr），并计算尿微量白蛋白/肌酐（UACR）和肾小球滤过率（eGFR），包括eGFRMDRD和eGFRCKD-EPI；进行治疗前后肝肾阴虚证评分；检测治疗前后血清TGF-β1，PAI-1，IL-1β和TNF-α水平，进行安全性评价。结果：观察组中医证候疗效总有效率为89.09%，优于对照组的77.27%，组间差异有统计学意义（χ2=5.491，P<0.05）；治疗后观察组β2-MG，CysC，NAG，mALB和SCr水平均低于对照组（P<0.01）；治疗后观察组UACR低于对照组，eGFRMDRD和eGFRCKD-EPI均高于对照组（P<0.01）；治疗后观察组患者血清TGF-β1，PAI-1，IL-1β和TNF-α水平均低于对照组（P<0.01）；两组患者均未发现与中药相关不良反应。结论：当归补血汤合六味地黄汤治疗早期高血压肾损害，能减临床症状，减轻早期肾损伤，延缓肾损害进展，并能调节TGF-β1，PAI-1，IL-1β和TNF-α等因子，起到保护肾损伤的作用。

Abstract

Objective: To observe the clinical effect of Danggui Buxuetang and Liuwei Dihuang Tang on early hypertensive renal damage

and its impact on levels of transforming growth factor-β1(TGF-β1)

plasminogen activator inhibitor-1 (PAI-1)

interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). Method: Two hundred and forty patients were divided into control group (120 cases) and observation group (120 cases) by random number table. Both groups were given valsartan capsules

80 mg/time

1 time/day

and nifedipine controlled release tablets were additionally provided to those beyond blood pressure standard

1 tablet/time

1 time/day. Control group took Liuwei Dihuang Tang

1 dose/day; Observation group took Danggui Buxuetang combined with Liuwei Dihuang Tang

1 dose/day. The course of treatment for both of the groups was 12 weeks. And levels of β2-microglobulin (β2-MG)

urinary N-acetyl-β-glucosaminidase (NAG)

cystatin (CysC)

microalbumin (mALB) and serum creatinine (SCr) were detected. Urinary albumin/creatinine (UACR) and glomerular filtration rate (eGFR)

including eGFRMDRD and eGFRCKD-EPI

were calculated. Before and after treatment

scores of liver and kidney Yin deficiency were graded. Levels of TGF-β1

PAI-1

IL-1β and TNF-α were detected

and adverse reactions were evaluated. Result: Total effective rate of traditional Chinese medicine(TCM) syndrome in observation group was 89.09%

which was higher than 77.27% in control group

with statically significant intergroup differences (χ2=5.491

P<0.05). After treatment

levels of β2-MG

CysC

NAG

mALB

SCr and UACR in observation group were lower than those in control group (P<0.01). And levels of eGFRMDRD and eGFRCKD-EPI in observation group were higher than those in control group (P<0.01). And levels of TGF-β1

PAI-1

IL-1β and TNF-α in observation group were lower than those in control group (P<0.01). No adverse reaction was found in both of the groups. Conclusion: Danggui Buxuetang combined with Liuwei Dihuang Tang can protect kidney by relieving clinical symptoms and early kidney injury

prolonging progress in renal damage

and regulating levels of TGF-β1

PAI-1

IL-1β and TNF-α.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

加味真武汤辨治慢性心力衰竭阳气亏虚证心肌纤维化的临床观察

中药离子导入联合玻璃酸钠膝关节腔注射治疗早中期膝骨性关节炎

清热活血散结复方对放射性肺炎及肺纤维化血清细胞因子IL-6,TNF-,TGF-1水平的影响

宣肺平喘胶囊对慢性阻塞性肺疾病大鼠模型的影响

车前子多糖治疗大鼠膜性肾病的实验探讨